Mania News and Research

RSS

New systematic study for managing treatment-resistant bipolar depression

Depression in bipolar illness is often difficult to treat and life-threating. Frequently it fails to respond to standard treatments. In the current issue of Psychotherapy and Psychosomatics a new drug combination is suggested.

27 Oct 2009

Researchers stress the importance of ensuring quality psychiatric treatment in general practice settings

Fifty-nine percent of all prescriptions filled for psychotropic medications are written by general practitioners, according to a research report published this month in Psychiatric Services.

1 Oct 2009

Metabolic Research to participate in the Olympia Expo

Metabolic Research, Inc., makers of Stemulite, will have a booth in the Olympia Expo at the Las Vegas Convention Center South Hall, September 25th and 26th. The Stemulite booth will feature Corey and Paul Simpson, well-known super athlete trainers joined by Cristi Cuellar, Miss Bikini Mexico International Elite Champion.

18 Sep 2009

GOP sees chance for revival as Democrats struggle with health proposals

"Republicans finally have a little spring back in their step thanks to a health care debate that has done more to cool off Obama-mania and reignite the conservative base than even most of its leaders had hoped," Politico reports.

18 Aug 2009

Schering-Plough announces European filing of Sycrest (asenapine) for schizophrenia and bipolar I disorder

Schering-Plough Corporation has announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for Sycrest (asenapine) sublingual tablets for the treatment of schizophrenia and manic episodes associated with bipolar I disorder. The application will follow the Centralized Procedure.

2 Jun 2009

Repligen licenses uridine patent rights for treatment of bipolar disorder

Repligen Corporation has announced that it has exclusively licensed worldwide rights for the use of uridine in the treatment of patients with bipolar disorder from McLean Hospital.

31 Mar 2009

FDA approves Symbyax for treatment-resistant depression

The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company has announced.

23 Mar 2009

Happy pills in America -- Our complex love affair with designer consciousness

The spectacular increase in the use of psychiatric drugs over the past 50 years involved what a University at Buffalo historian calls "a massive break with what we consider 'normal' mental health," one linked to myriad social and cultural changes in America.

19 Mar 2009

Cephalon announces positive results from study of NUVIGIL in bipolar depression

Cephalon, Inc. has announced positive results from a phase two clinical trial of NUVIGIL(R) (armodafinil) Tablets [C-IV] as adjunctive therapy for treating major depressive disorder in adults with bipolar I disorder.

17 Mar 2009

Shire withdraws European application for Daytrana (Methylphenidate Transdermal System)

Shire plc has announced that it has decided to withdraw the European Marketing Authorization Application (MAA) for Daytrana (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

16 Mar 2009

Schering-Plough submits response to FDA for SAPHRIS (asenapine) in the acute treatment of schizophrenia and bipolar I disorder

Schering-Plough Corporation has announced that it has responded to the U.S. Food and Drug Administration (FDA) complete response letter for SAPHRIS (asenapine) sublingual tablets, which was received in January 2009.

22 Feb 2009

New treatment approach needed for management of depression with bipolar disorder

In a study published in The American Journal of Psychiatry, a team of researchers led by Mayo Clinic psychiatrist Mark Frye, M.D., attempted to identify what factors make some people with bipolar depression more likely to experience treatment-emergent mania (TEM).

15 Feb 2009

Bipolar disorders linked to increased risk of early death from medical illness

Bipolar disorders appear to increase the risk of early death from a medical illness, according to a literature review study published as the lead article this week in the journal Psychiatric Services.

2 Feb 2009

Savella - Fibromyalgia treatment approved by FDA

Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.

19 Jan 2009

FDA issues complete response letter for SAPHRIS (asenapine) sublingual tablets in acute treatment of schizophrenia and bipolar disorder

Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy.

15 Jan 2009

Mania News and Research

New systematic study for managing treatment-resistant bipolar depression

Researchers stress the importance of ensuring quality psychiatric treatment in general practice settings

Metabolic Research to participate in the Olympia Expo

GOP sees chance for revival as Democrats struggle with health proposals

Schering-Plough announces European filing of Sycrest (asenapine) for schizophrenia and bipolar I disorder

Repligen licenses uridine patent rights for treatment of bipolar disorder

FDA approves Symbyax for treatment-resistant depression

Happy pills in America -- Our complex love affair with designer consciousness

Cephalon announces positive results from study of NUVIGIL in bipolar depression

Shire withdraws European application for Daytrana (Methylphenidate Transdermal System)

Schering-Plough submits response to FDA for SAPHRIS (asenapine) in the acute treatment of schizophrenia and bipolar I disorder

New treatment approach needed for management of depression with bipolar disorder

Bipolar disorders linked to increased risk of early death from medical illness

Savella - Fibromyalgia treatment approved by FDA

FDA issues complete response letter for SAPHRIS (asenapine) sublingual tablets in acute treatment of schizophrenia and bipolar disorder

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Swiss approval for Zevtera in treatment of complicated skin and soft tissue infections

Researchers say bipolar disorder also afflicts children

Older fathers more likely to have children with bipolar disorder

Children of older fathers more likely to have bipolar disorder

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News